Lupin launches Liraglutide Injection in US

04 Oct 2025 Evaluate

Lupin has launched Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen, in the United States (US). Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older, with type 2 diabetes mellitus. 

Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen (RLD Victoza) had an estimated annual sale of $350 million in the U.S. (IQVIA MAT August 2025). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2103.50 11.55 (0.55%)
05-Dec-2025 15:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.00
Dr. Reddys Lab 1278.00
Cipla 1521.25
Zydus Lifesciences 932.30
Lupin 2103.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×